Zip, If I could ask Alex Denner any question it would be is he aware of the potential of Vascepa (or an EPA derivative) as an adjunct drug for any cancer drug/therapy? If he his, could that be a selling point in getting a BP to acquire AMRN? (I really would like to know if people such as him or Dr. Bhatt believe that area would be worth pursuing.) It bothers me that is an area that is not even discussed except for the occasional comment by you or me. The potential if EPA were proven effective would be potentially massive...Yet, there really appears to be no interest (by AMRN management at least) in finding this out. I have mentioned years ago that a trial could be run with Keytruda that would be relatively simple to do. Why wouldn't someone like Dr. Bhatt pursue this?
Market Data 
Markets 
